BioCentury
ARTICLE | Financial News

SGP meets reduced EPS estimates

July 23, 2003 7:00 AM UTC

Schering-Plough (SGP) reported second quarter EPS of $0.12, meeting the Street's consensus, and in line with its July 7 profit warning (see BioCentury Extra, Monday July 7, 2003). Prior to the profit warning, analysts were expecting $0.18 EPS for the quarter. SGP's second quarter EPS were down 72% from the $0.43 reported in the second quarter 2002, reflecting continued competition for its allergy products and Peg-Intron/ Rebetol combination therapy for hepatitis C (HCV) infection. ...